Frontline medical professionals—led by groups like the Infectious Diseases Society of America—are calling for an overhaul of sepsis treatment. 

Why?

Because they see that current "checklist" approaches often don't boost survival and can even cause issues like antibiotic overuse.

The demand is clear: patients need solutions that deliver real results.

Eliaz Therapeutics is answering that call. From day one, we engineered XGal-3® to be different—to strike sepsis at its root by removing the critical inflammatory driver, Galectin-3.

This focus on real patient outcomes creates a powerful opportunity: to potentially save millions of lives and for investors to fuel a vital $62B market solution.

Sepsis won't wait.

Your investment—new or renewed—powers our mission to bring our solution to market. Consider joining us or deepening your support to help turn the tide!

🚩Invest in Eliaz Therapeutics today!

With gratitude, 

The Eliaz Therapeutics Team